Maya Goldman

Here’s what to know about the federal healthcare policies that will expire when the COVD-19 public health emergency declaration ends in May.

Some industry leaders and trade groups hope for an end-of-year lame duck package that reflects their priorities, while others point to the bipartisan potential of future endeavors.

Dr. Meena Seshamani, director of the Center for Medicare at the Centers for Medicare and Medicaid Services, discusses the importance of stakeholder collaboration and engagement.

Congress must pass legislation funding the government to avoid a shutdown on Friday. Medicare provisions for rural hospitals are under consideration.

The American Hospital Association and American Medical Association also hinted they may press their legal cases against the No Surprises Act.

CMS delayed its billing policy for visits provided by both a physician and non-physician provider, but the move could lead to a 15% pay cut for certain visits if the agency doesn't make changes, provider groups warn.

An analysis of the FDA's emergency use authorization process underscores the need for a national testing strategy, HHS inspectors said. 

The healthcare lobbying groups say the August final rule on surprise billing arbitration still poses concerns for providers. 

Regulators announced last year that they would delay the No Surprises Act's advanced explanation of benefits requirement and part of its good faith estimate provision. 

Lawmakers seek to limit how insurers require beneficiaries to get approval for medical care.

A group of 375 organizations, including the Federation of American Hospitals and the American Medical Association, asked Senate leaders to pass a two-year extension of telehealth flexibilities.

Value-based care advocates generally support CMS' plans for the Medicare Shared Savings Program but argue the agency should do more to support the initiative.

The federal government won't consider whether immigrants enroll in programs such as Medicaid when making permanent residency determinations.

Once the federal supply of coronavirus vaccines and treatments runs out, health insurers, employers and pharmacy benefit managers must start negotiating with drug manufacturers over prices.

Medicare Advantage and Part D sponsors must inform consumers about new cost-sharing rules for insulin and vaccinations contained in the Inflation Reduction Act.